PVLA
Income statement / Annual
Last year (2025), Palvella Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Palvella Therapeutics Inc.'s net income was -$41.72 M.
See Palvella Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$25.90 M |
$31.42 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$2.78 M
|
$2.37 M
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$23.12 M
|
$29.05 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0.89
|
0.92
|
| Research and Development Expenses |
$22.84 M
|
$8.15 M
|
$8.79 M
|
$50.21 M
|
$64.20 M
|
| General & Administrative Expenses |
$15.76 M
|
$5.94 M
|
$3.08 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.76 M
|
$5.94 M
|
$3.08 M
|
$16.38 M
|
$16.68 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$38.60 M
|
$14.10 M
|
$11.87 M
|
$66.60 M
|
$80.88 M
|
| Cost And Expenses |
$38.60 M
|
$14.10 M
|
$11.87 M
|
$69.38 M
|
$83.25 M
|
| Interest Income |
$2.59 M
|
$642.00 K
|
$6.27 M
|
$721.00 K
|
$4.00 K
|
| Interest Expense |
$5.82 M
|
$4.32 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$0.00
|
$2.78 M
|
$2.37 M
|
| EBITDA |
-$35.90 M |
-$13.12 M |
$18.69 M |
-$30.50 M |
-$43.37 M |
| EBITDA Ratio |
0
|
0
|
0
|
-1.18
|
-1.38
|
| Operating Income Ratio |
0
|
0
|
0
|
-1.68
|
-1.65
|
| Total Other Income/Expenses Net |
-$3.11 M
|
-$3.34 M
|
$30.56 M
|
$10.20 M
|
$6.09 M
|
| Income Before Tax |
-$41.72 M
|
-$17.43 M
|
$18.69 M
|
-$33.28 M
|
-$45.74 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-1.28
|
-1.46
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$41.72 M
|
-$17.43 M
|
$18.69 M
|
-$33.28 M
|
-$45.74 M
|
| Net Income Ratio |
0
|
0
|
0
|
-1.28
|
-1.46
|
| EPS |
-3.71 |
-7.83 |
14.74 |
-29.61 |
-56.69 |
| EPS Diluted |
-3.71 |
-7.83 |
14.74 |
-29.61 |
-56.69 |
| Weighted Average Shares Out |
$11.25 M
|
$2.23 M
|
$1.27 M
|
$930.35 K
|
$806.84 K
|
| Weighted Average Shares Out Diluted |
$11.25 M
|
$2.23 M
|
$1.27 M
|
$930.35 K
|
$806.84 K
|
| Link |
|
|
|
|
|
